NATH BIO-GENES (I) LTD
NATHBIOGEN · General/Diversified · NSE
₹169
Current Market Price
Fair Value (DCF)
₹330
Margin of Safety
+95.1%
Updated 14h ago
YieldIQ Score
60/100
Piotroski F-Score
4/9
Economic Moat
Moderate
Confidence
56%
ROE
—
Debt/Equity
0.23
WACC
11.1%
Market Cap
₹321 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
7.6%
Return on capital employed
EV / EBITDA
9.7×
Enterprise multiple
Debt / EBITDA
2.5×
Leverage vs earnings
Interest Coverage
5.1×
EBIT covers interest
Current Ratio
1.89×
Short-term liquidity
Asset Turnover
0.36×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.4%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹169.1
Bear case
₹196.63
MoS +14.0%
Base case
₹329.94
MoS +48.7%
Bull case
₹420.45
MoS +59.8%
Ratio Trends
NATHBIOGEN · last 7 annual periods
ROE
6.0%
ROCE
7.6%
Operating Margin
—
Debt / Equity
0.19×
PE
7.7×
EV / EBITDA
6.5×
Historical Financials
NATHBIOGEN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹308 Cr | ₹278 Cr | ₹301 Cr | ₹333 Cr | ₹365 Cr | +4.4% |
| EBITDA | — | ₹-47.1 Cr | ₹51.8 Cr | ₹56.7 Cr | ₹58.1 Cr | — |
| EBIT | ₹65.6 Cr | ₹-52.8 Cr | ₹46.3 Cr | ₹50.7 Cr | — | -6.2% |
| PAT | ₹55.7 Cr | ₹-67.3 Cr | ₹35.0 Cr | ₹39.6 Cr | ₹38.6 Cr | -8.7% |
| EPS (diluted) | ₹29.29 | ₹-35.43 | ₹18.42 | ₹21.34 | — | -7.6% |
| CFO | ₹1.1 Cr | ₹17.1 Cr | ₹38.4 Cr | ₹70.3 Cr | ₹17.6 Cr | +99.2% |
| CapEx | — | — | — | — | ₹-7.9 Cr | — |
| FCF | — | — | — | — | ₹9.7 Cr | +0.0% |
| Total Assets | — | ₹739 Cr | ₹793 Cr | ₹880 Cr | ₹1026 Cr | +8.5% |
| Total Debt | — | — | ₹105 Cr | ₹105 Cr | ₹123 Cr | +4.0% |
| Shareholders' Equity | — | — | ₹573 Cr | ₹610 Cr | ₹644 Cr | +3.0% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
NATHBIOGEN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| NOVAAGRI NOVA AGRITECH LIMITED | +18.4% | 54 | Below Fair Value | 12.5% | — |
| IGCL INDOGULF CROPSCIENCES LTD | +33.9% | 65 | Below Fair Value | 12.2% | — |
| NAGAFERT NAGARJUN FERT AND CHE LTD | +400.0% | 37 | Below Fair Value | — | — |
| SHIVALIK SHIVALIK RASAYAN LIMITED | -66.2% | 27 | Data Limited | 3.1% | — |
| INDOUS INDO US BIOTECH LTD | +26.8% | 87 | Below Fair Value | 20.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for NATHBIOGEN in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. NATH BIO-GENES (I) LTD (NATHBIOGEN.NS) trades at 169.10 vs a model fair value of 329.94, a gap of 95.1%. Piotroski F-score: 4/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of NATHBIOGEN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for NATHBIOGEN →
Compare
Head-to-head with peers
Compare NATHBIOGEN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse NATHBIOGENNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.